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including most of those available today in 
the public domain. In contrast to the com-
monly expressed reservations among 
cancer researchers, as a group the breast 
cancer cell lines were found to be surpris-
ingly representative of the primary tumors. 
Although cell lines had a much higher num-
ber of genetic changes per sample than 
primary tumors, genetic events that were 
exclusively seen in the breast cancer cell 
lines were rare. As has been demonstrated 
with the extensively studied NCI-60 cancer 
cell line set (http://dtp.nci.nih.gov/index.
html), molecular profiles of cancer cell 
lines could help to identify pharmacoge-
nomic predictors of response to therapeu-
tic compounds. For example, Neve et al. 
(2006) treated cell lines with Herceptin and 
identified protein levels and genomic aber-
rations that were correlated with response 
and resistance. Indeed, if more cancer 
drug response data became available, this 
“UCB-51” set could be much more repre-
sentative and informative than the NCI-60 
data series for targeted exploration of thera-
peutic hypotheses in breast cancer.
As much as these two studies advance 
the field, there are also many important 
aspects that remain to be explored in the 
future. First of all, every clinical study is 
dependent on the patient selection and ther-
apies administered. These effects cannot be 
fully evaluated in retrospective studies. The 
present studies focused on amplifications, 
yet deletions and unbalanced translocations 
inactivating or activating cancer genes may 
also be important. As compared to the ?1 
Mb resolution of the BAC arrays used in 
these studies, the latest generation oligo-
array-based CGH can approach theoretical 
limits of about 10 kb across the nonrepeti-
tive genomic DNA. Transcriptional profiling 
technologies also continue to advance. For 
example, alternatively spliced versions of 
genes are detectable with exon-level anal-
ysis, and detection of noncoding RNAs 
may pinpoint new information. The pres-
ent studies focused on genetic profiles, but 
epigenetic profiling has also been shown to 
be of significant importance. Metabolic and 
proteomic fingerprints as well as the math-
ematical analysis and modeling of all the 
“omics” data are needed to complete a com-
prehensive understanding of the molecular 
deregulation of the breast cancer cells in 
vitro and in vivo. Finally, taking molecular 
profiles toward the clinical diagnostic setting 
is the “final frontier” and will require stan-
dardized technologies, quality control, and 
prospective testing in large series of patient 
cohorts. This is a major effort for any single 
molecular profiling platform, and an enor-
mous challenge for the clinical application 
of integrated multiplatform profiling.
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The concepts of stem cells being resistant to therapy, stem-like cells existing in brain tumors, and these tumors initially respond-
ing to therapy followed by recurrence are well documented. On this foundation, a recent paper in Nature has demonstrated that 
CD133-expressing glioma cells in vivo and in culture are relatively resistant to radiation. The mechanism of resistance involves 
the cell-cycle-regulating proteins CHK1/CHK2. The data raise many questions about the details of radiobiology of stem-like 
cells in their native environment within tumors in vivo. These answers may lead to better optimization of radiation treatments 
and schedules for these patients.Radiation biologists were the first to for-
mulate the concept of stem cells. The 
term “stem cell” was coined in the con-454	text of clonogenic cells surviving radiation 
that were able to repopulate the spleen 
(McCulloch and Till, 1960, 2005). In the gut, cells with a relatively low baseline 
proliferation rate were found to be rela-
tively resistant to radiation and respond cancer cell december	2006
	 p r e v i e w sto it with cell division, giving rise to cells 
that repopulate the crypt (Hornsey, 1973; 
Marshman et al., 2002).
Even though gliomas have a dismal 
prognosis, radiation is the most suc-
cessful nonsurgical treatment for them. 
In response to a full course of radiation, 
gliomas frequently respond but then recur. 
Medulloblastomas are even more sensitive 
to radiation than gliomas with cure rates of 
70% obtained in children old enough to tol-
erate the treatment. There has been a long 
debate over the role of stem or progeni-
tor cells in brain tumors. Stem or progeni-
tors cells are more sensitive to oncogenic 
stimulation and have been proposed to be 
the cell of origin for these tumors (Holland 
et al., 2000). Further, human gliomas and 
medulloblastomas have been shown to 
contain cells with stem cell properties such 
as neurosphere formation and self-renewal 
(Galli et al., 2004). Recently, expression 
of the cell surface marker CD133 was 
shown to stratify glioma cells with stem-
like character from those without it (Singh 
et al., 2004). CD133-expressing cells are 
much more capable of initiating tumors 
when transplanted into rodents than cells 
not expressing CD133. CD133 has since 
been regarded as a marker for stem cells 
in gliomas.
A paper recently published in Nature 
(Bao et al., 2006) has determined the effect 
of radiation on the D456MG and D54MG 
glioma cell lines and surgical glioma sam-
ples. Mice bearing D456MG xenograft 
tumors were treated with high-dose radia-
tion, resulting in an increased percentage 
of CD133+ cells and more aggressive 
tumors on serial transplantation. For ex vivo 
radiation, cells isolated from D54MG xeno-
grafts were treated with 5 Gy, resulting in 
a similar increase in CD133+ cells. Similar 
results were obtained with cells isolated 
from three human glioma surgical samples 
radiated ex vivo with 2 Gy. The percentage 
of CD133-expressing cells as analyzed 
by FACS also correlated with the rate of 
tumor formation when implanted in mice. 
CD133+ cells from the D456MG line and 
from primary tumors show a more robust 
activation of the DNA damage pathway 
than CD133− cells in response to 3 Gy, and 
CD133+ cells repaired DNA damage faster 
than CD133− cells. Insight into the mecha-
nism was revealed with the use of DBH, an 
inhibitor of CHK1/CHK2, which sensitized 
both the CD133+ and CD133− cells from 
D456MG and surgical specimens to radia-
tion. The data indicate that stem cells within 
gliomas are resistant to radiation at least cancer cell december	2006	in part due to an elevated DNA damage 
response and more rapid repair of the DNA 
damage. Higher radiation doses kill some 
CD133-expressing cells, which are likely 
to be a heterogeneous population. It is not 
clear what subset of these cells are rela-
tively radiation resistant and what subset 
are stem-like, but the data clearly indicate 
that there is some overlap between these 
two characteristics.
It is easy to generalize clean and sat-
isfying data such as this, although there 
are specific details in this study that should 
be kept in mind. Some of the experiments 
were done with the D456MG cell line 
that is wild-type for p53, ink4a-arf, and 
pten (Rich et al., 2005a), a rare genetic 
background for adult gliomas (Rich et al., 
2005b). Other experiments were done 
with the D54MG cell line that is mutant for 
ink4a-arf and pten but wild-type for p53. 
It is likely that the status of these genes 
are critical for the radiation effects of both 
responding and nonresponding cells. In 
many of the experiments, radiation was 
done on individual cells ex vivo; it is not 
known how similar the response of these 
cells would be if they were in their natu-
ral setting in vivo. Stem cells are thought 
to occupy a specific niche with support-
ive and interactive stroma; it is not clear 
what effect the niche has on the relative 
resistance of stem-like cells to radiation 
in vivo. Further, the radiation response of 
cells in the normoxic culture conditions 
used in this paper may or may not reflect 
the response of cells in the hypoxic envi-
ronment of a glioblastoma. In spite of any 
caveats, it seems clear that cells express-
Figure 1.	Stem-like	cells	in	brain	tumors
Immunofluorescence	 images	 of	 fresh-frozen	
sections	of	a	human	medulloblastoma	showing	
localized	regions	of	cells	expressing	the	stem	cell	
markers	nestin	(green)	and	Notch	receptor	(red)	
that	work	well	 in	histochemical	staining.	Nuclei	
are	stained	blue	with	dAPI.	Note	that	these	stem-
like	cells	are	located	in	a	specific	region,	or	niche,	
rather	than	distributed	randomly	throughout	the	
tumor.	Scale	bar,	20	µm.ing markers of stem cells exist in gliomas 
and that these cells are more resistant to 
radiation than other cells in the tumor.
Important papers such as this one 
often raise more questions than they 
answer. For example, where is the niche 
for glioma stem-like cells in vivo (Figure 
1)? Is the DNA damage response and 
rate of repair for stem-like cells in vivo in 
their niche also elevated? Does the niche 
provide additional protections to stem-
like cells that are independent of DNA 
damage response? Presumably, glioma 
stem-like cells are rarely in cycle in vivo; 
does this also contribute to their rela-
tively resistant character? Does radiation 
cause cell cycle arrest in the few stem-like 
cells that are cycling at the time of treat-
ment? What is the time interval between 
radiation treatment and the point where 
stem-like cells reenter the cell cycle? Are 
these cells sensitive to radiation when 
they reenter the cycle, and if so, can they 
be synchronized and reradiated at their 
most sensitive point? Are there signaling 
pathways that contribute to the resistance 
phenotype in these cells? Are there small-
molecule inhibitors of signaling pathways 
already available that could reduce the 
radiation resistance specifically of the 
stem-like cell population in vivo? Would 
the recurrent tumor arising from the resis-
tant stem cells have the same radiation 
sensitivity as the spectrum of cells in the 
original tumor? Finally, could a rationally 
designed dosing schedule for radiation be 
combined with small-molecule inhibitors 
to result in a more effective treatment for 
these patients?
Certainly this paper will stir up discus-
sion in the brain tumor field. It lends sup-
port for functional cellular heterogeneity in 
gliomas and for the existence of stem-like 
cells as defined by expression of markers, 
formation of neurospheres, and tumor-ini-
tiating capacity. It hopefully will go farther 
than that. We now need to address some 
these focused questions of brain tumor 
radiation biology in vivo. With the answers 
to these questions we will hopefully then 
have the tools to rationally change the 
standard of care for these patients.
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Tissue-specific stem cells are considered 
fertile soil for some of the mutations that 
contribute to the development of human 
cancers. However, the molecular mecha-
nisms by which these mutations give rise 
to cancer stem cells, or otherwise lead to 
neoplastic disease, are less well defined. 
This issue is of major importance, since 
the implicated pathways may be targets 
for molecular therapies, particu-
larly if they are selectively involved 
in cancer versus normal stem cell 
maintenance.
Of the many molecular patholo-
gies associated with acute myeloid 
leukemia (AML), one recurrently 
implicated gene is PU.1 (SPI1; 
Sfpi1, for Spleen focus-forming virus 
proviral integration), which codes for 
a transcription factor that is essen-
tial for normal myelomonocytic dif-
ferentiation and consequently also 
functions as a tumor suppressor 
(reviewed in Koschmieder et al., 
2005). Repressed PU.1 transcrip-
tion has been reported in AMLs har-
boring PML-RARα (Mueller et al., 
2006) or FLT3-ITD mutations, and 
the AML-associated oncoprotein 
AML1-ETO functionally inactivates 
PU.1 through displacement of its 
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in AML (Rosenbauer et al., 2004; Metcalf 
et al., 2006). Thus, PU.1 activity appears to 
be a target of several oncogenic signaling 
pathways in AML (Figure 1). However, the 
downstream genes that are critical media-
tors of its leukemia-suppressive role have 
hitherto been undefined.
In an elegant series of experiments, 
Steidl et al. (2006) have recently solved a 
significant piece of this puzzle by 
identifying Jun and Junb, members 
of the activator protein-1 (AP-1) 
family of transcriptional regulators, 
as critical effectors of the PU.1 
tumor suppressor pathway. Their 
studies employed a PU.1 knock-
down (PU.1 KD) mouse model that 
develops highly penetrant AML as 
a consequence of reduced PU.1 
expression caused by deletion of 
a critical upstream regulatory ele-
ment in the PU.1 gene. Global tran-
scriptional analysis of an immature 
subfraction of bone marrow cells 
obtained from preleukemic PU.1 
KD mice identified Jun and Junb, 
in addition to a number of previ-
ously known PU.1 targets, to be 
downregulated compared with 
cells obtained from wild-type mice. 
The compared cell populations, 
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